Skip to content

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.7×0.0×
AbbVie logo
AbbVieABBV
46.6×+38.6×
Allogene Therapeutics logo
Allogene TherapeuticsALLO
0.3×+0.1×
Regenxbio logo
RegenxbioRGNX
3.4×+3.1×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-0.3×

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Current ratio8.8×+7.0×

Where this comes from

Calculated from Immix Biopharma, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s debt-to-equity?
Immix Biopharma, Inc. (IMMX) reported debt-to-equity of 0× in Q1 2026.
How has Immix Biopharma, Inc.'s debt-to-equity changed year-over-year?
Immix Biopharma, Inc.'s debt-to-equity decreased by 88.9% year-over-year, from 0.1× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.